SU1093245A3 - Способ получени амидов лактам- @ -уксусных кислот - Google Patents

Способ получени амидов лактам- @ -уксусных кислот Download PDF

Info

Publication number: SU1093245A3
Authority: SU; USSR - Soviet Union
Prior art keywords: pyrrolidinone; oxo; spectrum; multiplet; lactam
Prior art date: 1978-05-08

Application number

SU792763201A

Other languages

English (en)

Russian (ru)

Inventor

Родригес Людовик

Маршаль Люсьен

Original Assignee

Юцб С.А. (Фирма)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-05-08

Filing date

1979-05-08

Publication date

1984-05-15

1979-05-08 Application filed by Юцб С.А. (Фирма) filed Critical Юцб С.А. (Фирма)

1984-05-15 Application granted granted Critical

1984-05-15 Publication of SU1093245A3 publication Critical patent/SU1093245A3/ru

Links

238000004519 manufacturing process Methods 0.000 title claims 2
150000001408 amides Chemical class 0.000 title abstract description 14
239000002253 acid Substances 0.000 title description 2
150000007513 acids Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 16
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract description 8
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract description 8
239000001257 hydrogen Substances 0.000 claims abstract description 7
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 4
125000000068 chlorophenyl group Chemical group 0.000 claims abstract description 4
230000003993 interaction Effects 0.000 claims abstract description 4
150000002596 lactones Chemical class 0.000 claims abstract description 4
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
229910052783 alkali metal Inorganic materials 0.000 claims abstract description 3
150000001340 alkali metals Chemical class 0.000 claims abstract description 3
239000012442 inert solvent Substances 0.000 claims abstract description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 5
150000001412 amines Chemical class 0.000 claims description 2
IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 4
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 30
239000000047 product Substances 0.000 description 28
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
238000001819 mass spectrum Methods 0.000 description 16
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 16
238000002329 infrared spectrum Methods 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
239000007788 liquid Substances 0.000 description 11
238000002360 preparation method Methods 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
-1 iodine lactone Chemical class 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
230000000694 effects Effects 0.000 description 5
230000009501 mnemonic process Effects 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
MOVPZRXYGQFUHJ-UHFFFAOYSA-N 1-(2-oxooxolan-3-yl)pyrrolidin-2-one Chemical compound O=C1OCCC1N1C(=O)CCC1 MOVPZRXYGQFUHJ-UHFFFAOYSA-N 0.000 description 3
238000001816 cooling Methods 0.000 description 3
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000012360 testing method Methods 0.000 description 3
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
239000003480 eluent Substances 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229960004526 piracetam Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
BQKUBCIMCPRBFP-UHFFFAOYSA-N 1-(2-oxooxolan-3-yl)piperidin-2-one Chemical compound O=C1OCCC1N1C(=O)CCCC1 BQKUBCIMCPRBFP-UHFFFAOYSA-N 0.000 description 1
GCFJNFBTOMEQBC-UHFFFAOYSA-N 3,5-dimethyl-1-(2-oxooxolan-3-yl)pyrrolidin-2-one Chemical compound CC1CC(C)C(=O)N1C1C(=O)OCC1 GCFJNFBTOMEQBC-UHFFFAOYSA-N 0.000 description 1
AOCWQPKHSMJWPL-UHFFFAOYSA-N 3-methylpyrrolidin-2-one Chemical compound CC1CCNC1=O AOCWQPKHSMJWPL-UHFFFAOYSA-N 0.000 description 1
BNYSLJONCMUYLX-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-(2-oxooxolan-3-yl)-3-phenylpyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1C1C(C=2C=CC=CC=2)C(=O)N(C2C(OCC2)=O)C1 BNYSLJONCMUYLX-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
241001331845 Equus asinus x caballus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
241000907681 Morpho Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
101100293693 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) STO1 gene Proteins 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
101150050497 cbc1 gene Proteins 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000003902 lesion Effects 0.000 description 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
USISRUCGEISZIB-UHFFFAOYSA-N piperidin-3-one Chemical compound O=C1CCCNC1 USISRUCGEISZIB-UHFFFAOYSA-N 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000001144 postural effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
239000011345 viscous material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
- C07D227/02—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D227/06—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D227/08—Oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Cephalosporin Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Polyamides (AREA)

SU792763201A 1978-05-08 1979-05-08 Способ получени амидов лактам- @ -уксусных кислот SU1093245A3 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB1816078		1978-05-08

Publications (1)

Publication Number	Publication Date
SU1093245A3 true SU1093245A3 (ru)	1984-05-15

Family

ID=10107678

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SU792763201A SU1093245A3 (ru)	1978-05-08	1979-05-08	Способ получени амидов лактам- @ -уксусных кислот
SU792847114A SU969701A1 (ru)	1978-05-08	1979-11-26	Оксо-2-пирролидино-1-уксусные кислоты,или их амиды, или их дициклогексиламиновые соли, про вл ющие активность по отношению к мнемоническим процессам

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SU792847114A SU969701A1 (ru)	1978-05-08	1979-11-26	Оксо-2-пирролидино-1-уксусные кислоты,или их амиды, или их дициклогексиламиновые соли, про вл ющие активность по отношению к мнемоническим процессам

Country Status (23)

Country	Link
US (1)	US4221789A (2)
EP (1)	EP0005689B1 (2)
JP (1)	JPS54154760A (2)
AT (1)	ATE27T1 (2)
AU (1)	AU522815B2 (2)
BE (1)	BE876067A (2)
CA (1)	CA1119593A (2)
DE (2)	DE2960194D1 (2)
DK (1)	DK150064C (2)
ES (1)	ES480299A1 (2)
FI (1)	FI66602C (2)
FR (1)	FR2425433A1 (2)
GR (1)	GR67631B (2)
HU (1)	HU178362B (2)
IT (1)	IT7948950A0 (2)
NL (1)	NL7903536A (2)
NO (1)	NO150639C (2)
PL (1)	PL117056B1 (2)
PT (1)	PT69582A (2)
SE (1)	SE7903864L (2)
SU (2)	SU1093245A3 (2)
YU (1)	YU41340B (2)
ZA (1)	ZA792175B (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2944456C2 (de) *	1979-11-03	1982-04-01	Hoechst Ag, 6000 Frankfurt	Verfahren zur Herstellung von N-α -Alkoxyalkyl-carbonsäureamiden
US4396616A (en) *	1981-09-04	1983-08-02	Merck & Co., Inc.	Substituted enantholactam derivatives as antihypertensives
EP0089900B1 (en) *	1982-03-24	1985-12-27	Prodes S.A.	New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
US4608201A (en) *	1984-05-21	1986-08-26	Ppg Industries, Inc.	Process for preparing lactam imides
CA1322199C (en) *	1987-07-15	1993-09-14	Masami Eigyo	N-¬(2-oxopyrrolidin-1-yl) acetyl)\| piperazine derivatives and drug for senile dementia
IT1242043B (it) *	1990-12-21	1994-02-02	Sigma Tau Ind Farmaceuti	Derivati della 1,2,3,4,-tetraidronaftilammina ad attivita' nootropica e composizioni farmaceutiche che li contengono.
IT1245870B (it) *	1991-06-05	1994-10-25	Sigma Tau Ind Farmaceuti	3-acilammino-2-pirrolidinoni quali attivatori dei processi di appremdimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US5510477A (en) *	1994-03-01	1996-04-23	The Procter & Gamble Company	Process for the acylation of lactams
AU1369001A (en) *	1995-12-13	2001-03-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US7834043B2 (en)	2003-12-11	2010-11-16	Abbott Laboratories	HIV protease inhibiting compounds
EP3260118B1 (en)	2008-10-16	2021-03-24	The Johns Hopkins University	Methods and compositions for improving cognitive function
US20110212928A1 (en) *	2010-02-09	2011-09-01	The Johns Hopkins University	Methods and compositions for improving cognitive function
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
EP2968220B1 (en)	2013-03-15	2021-05-05	Agenebio, Inc.	Methods and compositions for improving cognitive function
WO2014144663A1 (en)	2013-03-15	2014-09-18	The Johns Hopkins University	Methods and compositions for improving cognitive function
NZ738682A (en)	2015-05-22	2022-01-28	Agenebio Inc	Extended release pharmaceutical compositions of levetiracetam
CN108137549B (zh)	2015-08-05	2021-07-20	百时美施贵宝公司	取代的甘氨酸衍生的fxia抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2657215A (en) *	1950-03-10	1953-10-27	Goodrich Co B F	Method for the preparation of novel n-(2-carboxyalkyl) succinimides
DE1081896B (de) *	1959-03-28	1960-05-19	Bayer Ag	Verfahren zur Herstellung von ª-Amino-ª-hydroxycarbonsaeuren
GB1039113A (en)	1964-08-06	1966-08-17	Ucb Sa	New n-substituted lactams
GB1309692A (en) *	1970-02-13	1973-03-14	Ucb Sa	N-substituted lactams
US3751262A (en) *	1970-06-30	1973-08-07	Allied Chem	Ruminant feed supplement
GB1539817A (en) *	1976-10-22	1979-02-07	Ucb Sa	N-substituted lactams

1979
- 1979-05-02 AT AT79870012T patent/ATE27T1/de not_active IP Right Cessation
- 1979-05-02 DE DE7979870012T patent/DE2960194D1/de not_active Expired
- 1979-05-02 EP EP79870012A patent/EP0005689B1/fr not_active Expired
- 1979-05-03 NO NO791477A patent/NO150639C/no unknown
- 1979-05-03 FI FI791421A patent/FI66602C/fi not_active IP Right Cessation
- 1979-05-03 DK DK182379A patent/DK150064C/da not_active IP Right Cessation
- 1979-05-03 SE SE7903864A patent/SE7903864L/xx unknown
- 1979-05-04 NL NL7903536A patent/NL7903536A/xx not_active Application Discontinuation
- 1979-05-07 AU AU46816/79A patent/AU522815B2/en not_active Expired
- 1979-05-07 CA CA000325925A patent/CA1119593A/en not_active Expired
- 1979-05-07 PT PT69582A patent/PT69582A/pt unknown
- 1979-05-07 US US06/036,987 patent/US4221789A/en not_active Expired - Lifetime
- 1979-05-07 ES ES480299A patent/ES480299A1/es not_active Expired
- 1979-05-07 PL PL1979215420A patent/PL117056B1/pl unknown
- 1979-05-07 BE BE1/9378A patent/BE876067A/xx unknown
- 1979-05-07 GR GR59038A patent/GR67631B/el unknown
- 1979-05-07 FR FR7911537A patent/FR2425433A1/fr not_active Withdrawn
- 1979-05-07 IT IT7948950A patent/IT7948950A0/it unknown
- 1979-05-07 ZA ZA792175A patent/ZA792175B/xx unknown
- 1979-05-08 YU YU1069/79A patent/YU41340B/xx unknown
- 1979-05-08 HU HU79UE94A patent/HU178362B/hu not_active IP Right Cessation
- 1979-05-08 DE DE19792918523 patent/DE2918523A1/de not_active Withdrawn
- 1979-05-08 SU SU792763201A patent/SU1093245A3/ru active
- 1979-05-08 JP JP5622979A patent/JPS54154760A/ja active Granted
- 1979-11-26 SU SU792847114A patent/SU969701A1/ru active

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1. Патент Англии 1039113, кл. С 2 С, опублик. 1963. 2.Патент Англии 1309692, кл. С 2 С, опублик. 1967. 3.Неницеску К.Д. Органическа хими . М., Иностранна литература, 1963, Т.1, с. 232, т.2, с.123. *

Also Published As

Publication number	Publication date
FI66602B (fi)	1984-07-31
DE2960194D1 (en)	1981-04-16
DK150064C (da)	1987-06-15
ES480299A1 (es)	1980-08-16
IT7948950A0 (it)	1979-05-07
EP0005689B1 (fr)	1981-03-18
US4221789A (en)	1980-09-09
YU106979A (en)	1983-04-30
EP0005689A1 (fr)	1979-11-28
CA1119593A (en)	1982-03-09
ATE27T1 (de)	1981-04-15
SU969701A1 (ru)	1982-10-30
FI66602C (fi)	1984-11-12
JPS54154760A (en)	1979-12-06
HU178362B (en)	1982-04-28
PL215420A1 (2)	1980-02-11
DK182379A (da)	1979-11-09
PT69582A (fr)	1979-06-01
JPS6220982B2 (2)	1987-05-11
SE7903864L (sv)	1979-11-09
NO791477L (no)	1979-11-09
BE876067A (fr)	1979-11-07
DK150064B (da)	1986-12-01
NO150639C (no)	1984-11-21
DE2918523A1 (de)	1979-11-15
ZA792175B (en)	1980-05-28
AU522815B2 (en)	1982-06-24
NO150639B (no)	1984-08-13
FI791421A7 (fi)	1979-11-09
AU4681679A (en)	1979-11-15
FR2425433A1 (fr)	1979-12-07
PL117056B1 (en)	1981-07-31
YU41340B (en)	1987-02-28
GR67631B (2)	1981-09-01
NL7903536A (nl)	1979-11-12

Publication	Publication Date	Title
EP0084164B1 (de)	1987-01-28	Neue Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung
EP0338331B1 (de)	1992-10-21	1,3-Disubstituierte Pyrrolidine
US5705640A (en)	1998-01-06	O-carbamoyl-(d)-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
US4221789A (en)	1980-09-09	Lactam-N-acetic acids and their amides
DE69120899T2 (de)	1997-02-27	Neue N-Benzoylprolin-Derivate, Verfahren zur Herstellung und diese enthaltende Arzneimittel
Wessig et al.	1994	Asymmetric Synthesis of 3‐Hydroxyprolines by Photocyclization of N‐(2‐Benzoylethyl) glycinamides
CH675418A5 (2)	1990-09-28
EP0473550A1 (de)	1992-03-04	Indolonaphthyridine
EP0192255B1 (de)	1990-08-08	Bi-2H-pyrroli(di)ndione
CH634576A5 (de)	1983-02-15	Verfahren zur herstellung von aminoalkylpyrrolbenzoxaazaalkanen.
DE2747369C2 (2)	1987-11-12
DK152752B (da)	1988-05-09	Fremgangsmaade til fremstilling af l-sulpirid
DE69115135T2 (de)	1996-05-09	1-Alkyl-3-(Acylamino)-Epsilon-Caprolactame zur Verbesserung der Lernfähigkeit und des Gedächtnisses und diese enthaltende pharmazeutische Zubereitungen.
US4216221A (en)	1980-08-05	1,3-Disubstituted (2-thio)ureas
DE2933636A1 (de)	1980-03-20	Neue n-phenylindolinderivate, ihre herstellung und pharmazeutische praeparate, welche diese verbindungen enthalten
EP0412058A1 (en)	1991-02-06	1-acyl-2-pyrrolidinones as enhancers of learning and memory and pharmaceutical compositions containing same
DE69630184T2 (de)	2004-08-12	Verfahren zur Herstellung von 1-substituierten Pyrrol-3-carbonsäure-Derivaten
IE45544B1 (en)	1982-09-22	Aptically active n-substituted pyrrolidines
WO1999054298A1 (de)	1999-10-28	Verfahren zur herstellung von enantiomerenreinem n-methyl- n-[(1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid
FI77443C (fi)	1989-03-10	Foerfarande foer framstaellning av farmaceutiskt anvaendbara 1-aroyl-5-oxo-2-pyrrolidinpropansyror och deras estrar.
DD292913A5 (de)	1991-08-14	Verfahren zur herstellung neuer benzothiopyranylamine
Kundu et al.	2011	Silicon-mediated asymmetric synthesis of fagomine and 3, 4-di-epi-fagomine
Kruse et al.	1988	Single‐step conversion of aliphatic, aromatic and heteroaromatic primary amines into piperazine‐2, 6‐diones
DE69502371T2 (de)	1998-12-17	O-Arylmethyl-N-(thio)acyl-hydroxylamine als Liganden des Melatoninrezeptors, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DD252829A5 (de)	1987-12-30	Verfahren zur herstellung von 5-aminoalkyl-beta-corbelinderivaten